期刊论文详细信息
Cancers
Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol
on behalf of the Dutch Pancreatic Cancer Group1  Joyce Bakker2  Johanna W. Wilmink2  Hans J. van der Vliet2  Tanja D. de Gruijl2  C. Willemien Menke-van der Houven van Oordt2  Johanna E. E. Pouw2  Daniela E. Oprea-Lager3  Bart Geboers3  Sanne Nieuwenhuizen3  Hester J. Scheffer3  Florentine E. F. Timmer3  Martijn R. Meijerink3  Jan J. J. de Vries3  Madelon Dijkstra3  Evelien A. C. Schouten3  Robbert S. Puijk3  Alette H. Ruarus3  M. Petrousjka van den Tol4 
[1] ;Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands;Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands;Department of Surgery, Amsterdam University Medical Centers, de Boelelaan 1117, 1081 HV Amsterdam, The Netherlands;
关键词: irreversible electroporation (IRE);    nivolumab;    IMO-2125;    CpG-ODN;    metastatic pancreatic cancer;    PDAC;   
DOI  :  10.3390/cancers13153902
来源: DOAJ
【 摘 要 】

Irreversible electroporation (IRE) is a novel image-guided tumor ablation technique with the ability to generate a window for the establishment of systemic antitumor immunity. IRE transiently alters the tumor’s immunosuppressive microenvironment while simultaneously generating antigen release, thereby instigating an adaptive immune response. Combining IRE with immunotherapeutic drugs, i.e., electroimmunotherapy, has synergistic potential and might induce a durable antitumor response. The primary objective of this study is to assess the safety of the combination of IRE with IMO-2125 (a toll-like receptor 9 ligand) and/or nivolumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In this randomized controlled phase I clinical trial, 18 patients with mPDAC pretreated with chemotherapy will be enrolled in one of three study arms: A (control): nivolumab monotherapy; B: percutaneous IRE of the primary tumor followed by nivolumab; or C: intratumoral injection of IMO-2125 followed by percutaneous IRE of the primary tumor and nivolumab. Assessments include contrast enhanced computed tomography (ceCT), 18F-FDG and 18F-BMS-986192 (PD-L1) positron emission tomography (PET)-CT, biopsies of the primary tumor and metastases, peripheral blood samples, and quality of life and pain questionnaires. There is no curative treatment option for patients with mPDAC, and palliative chemotherapy regimens only moderately improve survival. Consequently, there is an urgent need for innovative and radically different treatment approaches. Should electroimmunotherapy establish an effective and durable anti-tumor response, it may ultimately improve PDAC’s dismal prognosis.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次